Company Analysis
Sign in

Eupraxia Pharmaceuticals Inc. (EPRX)

Nasdaq: EPRX · Pharmaceutical Preparations · Victoria, BC · filing with the SEC since 2013
Full chart Alerts Compare
Grade6.5
◀ Past 5.9● Present 5.7▶ Future 7.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022
Report filedMar 13, 2026Mar 20, 2025Apr 1, 2024·
Revenue000·
Research and development21,331,65616,079,27620,363,124r13,629,854
General and administrative17,102,38310,924,1357,484,105r3,987,598
Total operating expenses38,434,03927,003,41127,847,22917,617,452
Interest expense0603,5731,170,173982,856
Interest and investment income1,412,5161,159,943862,969431,799
Total non-operating income (expense)-152,5221,260,726-1,082,354-1,373,312
Income before income taxes-38,586,561-25,742,685-28,929,583-18,990,764
Income tax expense19,0911,80436,4230
Income from continuing operations-41,106,986-25,928,093-28,220,796·
Net income including non-controlling interests-38,605,652-25,744,489-28,966,006-18,990,764
Net income to non-controlling interests-29,509-241,953-745,210-501,135
Net income-38,576,143-25,502,536-28,220,796-18,489,629
Preferred dividends2,530,843425,5570·
Earnings per share, basic-1.03-0.76-1.17-0.96
Earnings per share, diluted-1.03-0.76-1.17-0.96
Weighted average shares, basic39,956,13333,930,57524,146,62319,285,447
Weighted average shares, diluted39,956,13333,930,57524,146,62319,285,447
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Interest expense what its borrowing costus-gaap:InterestExpense
us-gaap:InterestExpenseNonoperating
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Income from continuing operations profit from the businesses it keepsus-gaap:IncomeLossFromContinuingOperations
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Preferred dividends paid to preferred holders before common shareholdersus-gaap:PreferredStockDividendsIncomeStatementImpact
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton EPRX · research, not advice